Drug discovery: a historical perspective.

@article{Drews2000DrugDA,
  title={Drug discovery: a historical perspective.},
  author={J{\"u}rgen Dr. Drews},
  journal={Science},
  year={2000},
  volume={287 5460},
  pages={
          1960-4
        }
}
  • J. Drews
  • Published 2000
  • Medicine, Biology
  • Science
Driven by chemistry but increasingly guided by pharmacology and the clinical sciences, drug research has contributed more to the progress of medicine during the past century than any other scientific factor. The advent of molecular biology and, in particular, of genomic sciences is having a deep impact on drug discovery. Recombinant proteins and monoclonal antibodies have greatly enriched our therapeutic armamentarium. Genome sciences, combined with bioinformatic tools, allow us to dissect the… Expand
Drug Discovery: An In Silico Approach
The field of drug research, guided by chemistry, pharmacology, and clinical sciences, has been a major contributor in progressing and development of medicine during the past century. The arrival ofExpand
HTS in the new millennium: the role of pharmacology and flexibility.
TLDR
Topics discussed include portfolio composition (molecular targets amenable to small molecule drug discovery), screening file content, assay formats and plating densities, and the impact of instrumentation on the ability of HTS to identify lead chemical matter. Expand
Stategic trends in the drug industry.
  • J. Drews
  • Medicine
  • Drug discovery today
  • 2003
TLDR
The promise of genomics in drug discovery, which was eagerly embraced in the mid-1990s, has not yet been fulfilled, but the influence of modern biology on drug discovery remains viable and the first tier of the biotechnology industry has now become the most productive segment of the drug industry. Expand
Genome Sequencing and Genomic Technologies in Drug Discovery and Development
TLDR
The attrition rate of the drug discovery and development pipeline continues to be a major problem, as highlighted by the large number of compounds that fail in clinical trials because of poor pharmacology, toxicity, and/or lack of efficacy. Expand
The Future for Genomic Medicine in Inflammatory Diseases
Identifying novel drug targets in the pharmaceutical industry pushes the boundaries of disease understanding and maintains a competitive arena. Finding new ways to drug these targets may allowExpand
Drug discovery processes to drug targeting mechanisms
TLDR
The review will describe the preclinical stages, identification and validation of target through HTS (high throughput screening assay) and finally approval of drug molecule for further clinical development. Expand
Genomics, New Drug Development, and Precision Medicines
TLDR
This chapter will introduce the major concepts of new drug discovery and development, and give a broad overview of how genetics and genomics is used across the whole drugiscovery and development pipeline, from pretarget identification to postmarketing surveillance to help discover and develop improved medicines. Expand
Role of Medicinal Chemist in the Modern Drug Discovery and
TLDR
The previous era of modern drug discovery was dominated by chemistry, whereas now a more rational approach is employed where knowledge about enzymes and receptors has required a unique dialogue between chemists and biologists. Expand
Review of approaches from drug discovery process to drug targeting mechanisms
Drug discovery in different time frames provides reflection in the struggle of scientists to generate synthetic products from an atural source. The complex processes exist in the development of newExpand
DRUG DISCOVERY: AN APPRAISAL
TLDR
This review intends to present a comprehensive view of overall transition and modernization of the drug discovery process and it’s impacts on the scientific community. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 74 REFERENCES
Structural genomics: beyond the Human Genome Project
TLDR
A program of high-throughput X-ray crystallography aimed at developing a comprehensive mechanistic understanding of normal and abnormal human and microbial physiology at the molecular level is about to embark on. Expand
Antibody phage display technology and its applications.
TLDR
A combination of the design and generation of millions to billions of different ligands, together with phage display for the isolation of binding ligands and with functional assays for identifying (and possibly selecting) bio-active ligands will provide a powerful tool for drug and target discovery well into the next decade. Expand
Pharmacological rescue of mutant p53 conformation and function.
TLDR
Small synthetic molecules identified promoted the stability of wild-type p53 but also allowed mutant p53 to maintain an active conformation, enabling it to activate transcription and to slow tumor growth in mice. Expand
The molecular basis for growth hormone-receptor interactions.
TLDR
The data indicate that hGH binds to the hGH receptor on cell membranes through site 1 and subsequently forms dimers through site 2, and it is believed a similar process may occur for hGH to activate the hPRL receptor, except that Zn2+ is required for site 1 association. Expand
Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A.
TLDR
Compounds that interfere selectively with the calcineurin-NFAT interaction without affecting calcineURin phosphatase activity may be useful as therapeutic agents that are less toxic than current drugs. Expand
Bioactive Diversity and Screening Library Selection via Affinity Fingerprinting
TLDR
It is demonstrated how affinity fingerprints may be used in conjunction with simple algorithms to select active-enriched diverse training sets and to efficiently extract the most active compounds from a large library. Expand
Predicting ligand binding to proteins by affinity fingerprinting.
TLDR
An affinity fingerprint database, which provides a rich source of data defining operational similarities among proteins, can be used to test theories of cryptic homology unexpected from current understanding of protein structure. Expand
A humanized antibody that binds to the interleukin 2 receptor.
TLDR
A "humanized" antibody is constructed by combining the complementarity-determining regions (CDRs) of the anti-Tac antibody with human framework and constant regions and has an affinity for p55 of 3 x 10(9) M-1, about 1/3 that of murine anti- Tac. Expand
Designed molecules that fold to mimic protein secondary structures.
TLDR
A variety of compounds that mimic helices, turns, and sheets have been developed, with notable advances in the design of beta-peptides that mimic each of these structures. Expand
Phage-display technology--finding a needle in a vast molecular haystack.
TLDR
Screening of phage-displayed libraries of proteins and peptides has been used to solve an increasing diversity of problems, including identification of binding motifs for much smaller targets and the use of novel screening methods to identify chemical activities. Expand
...
1
2
3
4
5
...